Key Takeaways
- • KilgourMD, a Stanford-trained dermatologist-founded scalp health company, closed a Series A funding round led by New York-based Prelude Growth Partners, with participation from existing investors Willow Growth, Joyance Partners, and Able Partners.
- • The company has demonstrated strong commercial traction, selling one bottle of its proprietary two-step scalp serum system every 20 seconds and reporting a profitable 2025, positioning it as a differentiated player in the growing scalp health category.
- • Clinical validation supports the company's market position: a completed trial on menopausal women showed 95% of participants experienced reduced shedding within six weeks, with majority achieving clinically meaningful regrowth by four months; results accepted for publication in the Journal of Drugs in Dermatology.
- • Series A proceeds will fund expansion of KilgourMD's proprietary active ingredient pipeline, development of new product formulations, and clinical trials targeting underserved populations in hair loss treatment.
- • Prelude Growth Partners' Managing Partner Alicia Sontag joined the company's Board of Directors, signaling institutional conviction in the scalp health innovation opportunity and KilgourMD's founder-led, clinically grounded business model.
Summary
KilgourMD, a dermatologist-founded scalp health and hair growth company, has closed a Series A funding round led by Prelude Growth Partners, a New York-based growth equity firm specializing in high-growth consumer brands in health, wellness, and beauty. The round included participation from existing investors Willow Growth, Joyance Partners, and Able Partners. The company was founded in 2023 by Dr. James Kilgour, a Stanford-trained, board-certified dermatologist who developed the platform after witnessing firsthand the impact of menopause-related hair loss on his mother and numerous patients.
The investment reflects strong commercial momentum and clinical validation. KilgourMD reported selling one bottle of its proprietary two-step scalp serum system every 20 seconds and achieved profitability in 2025. The company's clinical credentials are substantive: a completed trial focused on menopausal women demonstrated that 95% of participants experienced reduced shedding within six weeks, with the majority achieving clinically meaningful regrowth by four months, as evaluated by independent board-certified dermatologists. These results have been accepted for publication in the Journal of Drugs in Dermatology, positioning the brand as clinically grounded rather than consumer-driven hype.
The Series A funding will support KilgourMD's expansion into three key areas: development of its proprietary active ingredient pipeline, formulation of new product offerings, and clinical trials targeting underserved populations in hair loss treatment. The company is positioned at the intersection of clinical dermatology and consumer hair care, treating scalp aging as a root cause of hair thinning. Beyond its core scalp serum system, KilgourMD offers treatment and prevention serums, shampoo, and conditioner formulations.
Board composition reinforces investor confidence. Alicia Sontag, Managing Partner at Prelude Growth Partners, joined the board alongside Dr. Kilgour, Deborah Benton (managing partner of Willow Growth and series seed lead investor), and COO Dr. Alok Prasad. Sontag characterized KilgourMD as "establishing themselves as thought leaders" with "exceptional consumer traction" and a "highly differentiated, clinically grounded platform." The investment addresses a market opportunity in menopause-related and gender-specific hair loss, a segment historically underserved by existing treatments and frequently overlooked by traditional dermatology and consumer health companies.
The investment reflects strong commercial momentum and clinical validation. KilgourMD reported selling one bottle of its proprietary two-step scalp serum system every 20 seconds and achieved profitability in 2025. The company's clinical credentials are substantive: a completed trial focused on menopausal women demonstrated that 95% of participants experienced reduced shedding within six weeks, with the majority achieving clinically meaningful regrowth by four months, as evaluated by independent board-certified dermatologists. These results have been accepted for publication in the Journal of Drugs in Dermatology, positioning the brand as clinically grounded rather than consumer-driven hype.
The Series A funding will support KilgourMD's expansion into three key areas: development of its proprietary active ingredient pipeline, formulation of new product offerings, and clinical trials targeting underserved populations in hair loss treatment. The company is positioned at the intersection of clinical dermatology and consumer hair care, treating scalp aging as a root cause of hair thinning. Beyond its core scalp serum system, KilgourMD offers treatment and prevention serums, shampoo, and conditioner formulations.
Board composition reinforces investor confidence. Alicia Sontag, Managing Partner at Prelude Growth Partners, joined the board alongside Dr. Kilgour, Deborah Benton (managing partner of Willow Growth and series seed lead investor), and COO Dr. Alok Prasad. Sontag characterized KilgourMD as "establishing themselves as thought leaders" with "exceptional consumer traction" and a "highly differentiated, clinically grounded platform." The investment addresses a market opportunity in menopause-related and gender-specific hair loss, a segment historically underserved by existing treatments and frequently overlooked by traditional dermatology and consumer health companies.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.